Ask AI
ProCE Banner Activity

Interactive Patient Toolkit: Tumor Factors and Treatment Options for Patients With Early-Stage Breast Cancer

PDF

Downloadable interactive patient toolkit to support selection of the most appropriate management for early-stage breast cancer based on patient considerations, goals, disease subtype, and optimal treatment approach, with examples of expert-selected treatment options for HR-positive, HER2-positive, and TNBC disease.

Released: July 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Tigerlily Foundation.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Tigerlily Foundation

ProCE Banner

Target Audience

This activity is intended for oncologists, nurses, nurse practitioners, physician associates, pharmacists, and other healthcare professionals who care for patients with early breast cancer. This educational program is also intended to reach patients with early breast cancer and their caregivers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recommend the optimal neo/adjuvant treatment strategy for each patient with EBC, considering patient/disease factors, evidence, approvals, and guidelines

  • Collaborate with patients, caregivers, and the multidisciplinary team to effectively monitor and manage treatment-related toxicities experienced by patients with EBC

  • Apply shared decision-making and communication strategies to support patient adherence and persistence on neo/adjuvant treatment for EBC

  • Evaluate strategies to mitigate disparities in guideline-concordant care, access to novel therapies and clinical trials, and supportive care in patients who are racial/ethnic minorities, older, and/or with comorbidities

  • Appraise the clinical implications of emerging evidence for neo/adjuvant treatments leveraging antibody–drug conjugates, immunotherapies, and other novel agents under investigation in EBC

Financial Disclosures

Primary Author

Kristen D. Whitaker, MD, MS: consultant/advisor/speaker: Lilly, Merck, Novartis.